Can Rexulti Cause Irregular Heart Rhythm?
Rexulti (brexpiprazole) does not cause clinically significant QT prolongation or irregular heart rhythms at therapeutic doses. According to FDA labeling, at doses 3-4 times the maximum recommended human dose, brexpiprazole does not prolong the QTc interval to any clinically relevant extent 1.
Evidence from Clinical Studies
The cardiac safety profile of brexpiprazole is notably favorable compared to many other antipsychotics:
- No clinically meaningful ECG effects: Clinical trials demonstrated no clinically relevant effects on the ECG QT interval 2, 3, 4
- Minimal QT prolongation: Research shows brexpiprazole causes 0 ms mean QT prolongation, which is negligible compared to other antipsychotics like ziprasidone (5-22 ms), haloperidol (7 ms), or quetiapine (6 ms) 5
- Low arrhythmia risk classification: Among antipsychotic drugs, brexpiprazole has negligible risk for QT prolongation, similar to aripiprazole and clozapine 6
Context Within Antipsychotic Class
While almost all antipsychotics cause some degree of QTc prolongation due to a quinidine-like effect 5, brexpiprazole stands out as having one of the lowest risks:
Higher-risk antipsychotics (avoid or use with extreme caution):
- Ziprasidone, iloperidone, asenapine, amisulpride (highest risk) 6
- Thioridazine (FDA black box warning) 5
Lower-risk antipsychotics (including brexpiprazole):
- Aripiprazole, clozapine, lurasidone, and brexpiprazole have negligible risk 6
Clinical Monitoring Recommendations
For brexpiprazole specifically, routine ECG monitoring is not required in otherwise healthy patients 6. However, consider baseline ECG if:
- Patient has pre-existing cardiac disease (history of MI, heart failure, conduction abnormalities) 1
- Concurrent use of other QT-prolonging medications 6
- Electrolyte disturbances present (hypokalemia, hypomagnesemia) 6
- Female sex, elderly age, or structural heart disease (higher baseline risk) 6
Important Caveats
Orthostatic hypotension is a more relevant cardiac concern with brexpiprazole than arrhythmia. In clinical trials, orthostatic hypotension occurred in 0.1-1% of patients, and syncope in 0.1-0.8% 1. Monitor orthostatic vital signs in vulnerable patients (elderly, dehydrated, on antihypertensives).
Drug interactions: While brexpiprazole itself has minimal cardiac effects, avoid combining with multiple QT-prolonging drugs. Check www.crediblemeds.org before adding other medications 6.
The evidence consistently demonstrates that brexpiprazole has one of the most favorable cardiac safety profiles among antipsychotics, with no clinically significant risk of irregular heart rhythms at therapeutic doses 1, 2, 3, 4.